Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Grill

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
British Journal of Clinical Pharmacology|May 7, 2020
Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjectsSimon Grill, Shirin Bruderer, Patricia N Sidharta, et al.
Frontiers in Pediatrics|July 5, 2021
Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A <i>Post-hoc</i> Analysis From the FUTURE 3 StudyMaurice Beghetti, Rolf M F Berger, Damien Bonnet, et al.
British Journal of Clinical Pharmacology|February 19, 2017
A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3Rolf M F Berger, Martine Gehin, Maurice Beghetti, et al.
Biochemistry|February 6, 2004
HMGB6 from Arabidopsis thaliana specifies a novel type of plant chromosomal HMGB proteinKlaus D Grasser, Simon Grill, Meg Duroux, et al.
Archives of Gynecology and Obstetrics|August 30, 2008
High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometrySimon Grill, Irina Banzola, Ying Li, et al.
Chest|December 22, 2025
A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertensionMaurice Beghetti, Lene Nygaard Axelsen, Julian I Borissoff, et al.
The Lancet. Infectious Diseases|February 3, 2019
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trialsDale N Gerding, Oliver A Cornely, Simon Grill, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
British Journal of Clinical Pharmacology|May 7, 2020
Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjectsSimon Grill, Shirin Bruderer, Patricia N Sidharta, et al.
Frontiers in Pediatrics|July 5, 2021
Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A <i>Post-hoc</i> Analysis From the FUTURE 3 StudyMaurice Beghetti, Rolf M F Berger, Damien Bonnet, et al.
British Journal of Clinical Pharmacology|February 19, 2017
A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3Rolf M F Berger, Martine Gehin, Maurice Beghetti, et al.
Biochemistry|February 6, 2004
HMGB6 from Arabidopsis thaliana specifies a novel type of plant chromosomal HMGB proteinKlaus D Grasser, Simon Grill, Meg Duroux, et al.
Archives of Gynecology and Obstetrics|August 30, 2008
High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometrySimon Grill, Irina Banzola, Ying Li, et al.
Chest|December 22, 2025
A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertensionMaurice Beghetti, Lene Nygaard Axelsen, Julian I Borissoff, et al.
The Lancet. Infectious Diseases|February 3, 2019
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trialsDale N Gerding, Oliver A Cornely, Simon Grill, et al.
Pageof 2